Onconetix, Inc. (ONCO)
3.15
+0.15
(+5.00%)
USD |
NASDAQ |
Nov 18, 16:00
3.15
0.00 (0.00%)
After-Hours: 19:58
Onconetix Enterprise Value : -4.615M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -4.615M |
| November 16, 2026 | -4.649M |
| November 13, 2026 | -4.536M |
| November 12, 2026 | -4.604M |
| November 11, 2026 | -4.327M |
| November 10, 2026 | -4.437M |
| November 09, 2026 | -4.395M |
| November 06, 2026 | -3.117M |
| November 05, 2026 | -3.670M |
| November 04, 2026 | -3.256M |
| November 03, 2026 | -3.595M |
| November 02, 2026 | -3.694M |
| October 30, 2026 | -3.625M |
| October 29, 2026 | -3.530M |
| October 28, 2026 | -3.485M |
| October 27, 2026 | -3.953M |
| October 26, 2026 | -4.239M |
| October 23, 2026 | -4.168M |
| October 22, 2026 | -4.21M |
| October 21, 2026 | -4.102M |
| October 20, 2026 | -4.212M |
| October 19, 2026 | -4.121M |
| October 16, 2026 | -3.937M |
| October 15, 2026 | -3.674M |
| October 14, 2026 | -3.674M |
| Date | Value |
|---|---|
| October 13, 2026 | -3.648M |
| October 12, 2026 | -3.513M |
| October 09, 2026 | -3.401M |
| October 08, 2026 | -3.271M |
| October 07, 2026 | -3.488M |
| October 06, 2026 | -3.245M |
| October 05, 2026 | -3.20M |
| October 02, 2026 | -2.970M |
| October 01, 2026 | -2.930M |
| September 30, 2026 | -2.785M |
| September 29, 2026 | -2.642M |
| September 28, 2026 | -1.542M |
| September 25, 2026 | -1.846M |
| September 24, 2026 | -2.297M |
| September 23, 2026 | -2.301M |
| September 22, 2026 | -3.162M |
| September 21, 2026 | -3.269M |
| September 18, 2026 | -3.329M |
| September 17, 2026 | -3.236M |
| September 16, 2026 | -3.236M |
| September 15, 2026 | -3.306M |
| September 14, 2026 | -3.335M |
| September 11, 2026 | -2.884M |
| September 10, 2026 | -2.786M |
| September 09, 2026 | -2.668M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vistagen Therapeutics, Inc. | -10.85M |
| BridgeBio Pharma, Inc. | 17.88B |
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.867M |
| Revenue (Quarterly) | 0.0171M |
| Total Expenses (Quarterly) | 2.884M |
| EPS Diluted (Quarterly) | -12.78 |
| Gross Profit Margin (Quarterly) | 25.15% |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -63.21K% |
| Normalized Earnings Yield | -80897.75 |